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Abstract
Background: Depression has serious personal, family and economic consequences. It 
is estimated that it will cost £12.15 billion to the economy each year in England by 
2026. Improving Access to Psychological Therapies (IAPT) is the National Health 
Service talking therapies service in England for adults experiencing anxiety or 
depression. Over 1 million people are referred to IAPT every year, over half 
experiencing depression. Where symptoms of depression are mild/moderate, people 
are typically offered Cognitive Behavioural Therapy (CBT) self-help supported by a 
psychological wellbeing practitioner (PWP). The problem is that over half of people 
who complete treatment for depression in IAPT remain depressed despite receiving 
National Institute of Health and Care Excellent (NICE) recommended treatment. 
Furthermore, less than half of IAPT service users complete treatment. This study 
seeks to investigate the effectiveness of an alternative to CBT self-help. Mindfulness-
based cognitive therapy differs from CBT in focus, approach and practice and may be 
more effective with a higher number of treatment completions. 
Methods/Design: This is a definitive randomised controlled trial comparing supported 
mindfulness-based cognitive therapy self-help (MBCT-SH) with supported cognitive 
behavioural therapy self-help (CBT-SH) for adults experiencing mild/moderate 
depression being treated in IAPT services. Four hundred and ten participants 
experiencing mild/moderate depression will be recruited from IAPT services and 
randomised to receive either an MBCT-based self-help workbook or a CBT-based 
self-help workbook. Participants will be asked to complete their workbook within 16 
4
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weeks, with six support sessions with a PWP. The primary outcome is depression 
symptom severity upon treatment completion. Secondary outcomes are treatment 
completion rates and measures of generalized anxiety, wellbeing, functioning and 
mindfulness. An exploratory non-inferiority analysis will be conducted in the event 
the primary hypothesis is not supported. A semi-structured interview with participants
will guide understanding of change processes.
Discussion: If the findings from this randomised controlled trial demonstrate that 
MBCT-SH is more effective than CBT-SH for adults experiencing depression, this 
will provide evidence for policy makers and lead to changes to clinical practice in 
IAPT services, leading to greater choice of self-help treatment options and better 
outcomes for service users. If the exploratory non-inferiority analysis is conducted 
and this indicates non-inferiority of MBCT-SH in comparison to CBT-SH this will 
also be of interest to policy makers when seeking to increase service user choice of 
self-help treatment options for depression. 
Trial registration: Current Controlled Trial registration number ISRCTN 13495752. 
Registered on 31 August 2017 (www.isrctn.com/ISRCTN13495752).
Protocol Version: Version 1 (18 January 2020)
Recruitment Status: Recruiting: participants are currently being recruited and enrolled
Date first participant randomised: 24 November 2017
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Trial Sponsor: Sussex Partnership NHS Foundation Trust 
(ResearchGovernance@sussexpartnership.nhs.uk)
Keywords: depression, mindfulness, cognitive behavioural therapy, mindfulness-
based cognitive therapy, self-help
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Background
Around 15% of adults in England experience clinically significant depression or 
anxiety in any week[1]. Improving Access to Psychological Therapies (IAPT) is an 
initiative launched in the National Health Service (NHS) in England In 2006 that aims
to improve access to psychological therapies for people experiencing anxiety and 
depression with over 1.5 million people now referred to IAPT each year[2]. 
Depression is typically recurrent - following one episode of major depression 50% 
will relapse and after two episodes 80% relapse[3]. In addition to the impact on 
individuals and their families, depression is estimated to cost the economy in England 
£12.15 billion a year by 2026[4]. In order to meet the needs of people experiencing 
depression IAPT typically offers stepped-care[5] – supported self-help at what is 
called ‘Step 2’ followed by, where needed, face-to-face therapy at ‘Step 3’. In line 
with National Institute of Health and Care Excellence (NICE)[6] guidelines, at Step 2 
people are provided with cognitive behavioural therapy self-help (CBT-SH) materials 
supported by a trained Psychological Wellbeing Practitioner (PWP). 
However, IAPT has shown modest treatment outcomes for CBT self-help - only 41% 
of people receiving book-based PWP-supported CBT self-help for depression met 
criteria for remission in the 2018-19 financial year[2]. In addition, this figure is for 
initial remission and does not consider sustained recovery[7]. Partial remission from 
depression is associated with greater risk of relapse[8]. A related problem in IAPT is 
high rates of treatment drop-out - only 36% of people referred to IAPT in 2018-19 
completed a course of treatment[2]. Completing treatment is important because it is 7
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associated with better outcomes[9]. Moreover, costs for treatment non-completers 
surpass that of treatment completers in IAPT[10]. Yet, there is poor understanding of 
reasons for non-completion[11], and this evidence gap needs addressing. Improving 
remission rates for depression and increasing treatment completion require urgent 
attention. 
Mindfulness is the capacity to pay attention, intentionally and non-judgmentally, to 
current experience. Mindfulness-based interventions (MBIs) teach the application of 
mindfulness in everyday life and work by reducing rumination and worry[12]. They 
address well-established mechanisms which trigger and maintain depression[13]. 
MBIs differ from CBT in important ways: (1) CBT includes evaluating the accuracy 
of difficult thoughts, MBIs encourage a self-compassionate, non-judgmental and 
accepting attitude towards experience, including unpleasant thoughts; (2) regular 
meditation practice (verbally guided attention towards present-moment experiences) 
is integral to MBIs but is not included in CBT- meditation is the training ground that 
enables participants to experience thoughts in the moment as transient mental 
events[14]; and (3) participant experience is different in terms of content and goals.
Mindfulness-based cognitive therapy (MBCT) is a group therapy recommended for 
relapse prevention for depression in the UK by the NICE[15] that includes elements 
of CBT for depression. Meta-analyses show MBCT reduces the relative risk of 
relapse for people with a history of multiple episodes of depression by 31%[16] . 
Mindfulness-based group interventions, in comparison to control conditions, lead to 
significant reductions in depression severity for people currently depressed[17]. Thus,
MBCT groups are a good candidate for not only attaining initial symptom remission 
8
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but also for achieving sustained recovery and preventing relapse. However, this 
evidence applies to formal face-to-face MBCT groups, delivered by highly trained 
MBCT therapists and we cannot assume this potential will generalise to a supported 
self-help intervention in a service such as IAPT. 
MBCT self-help (MBCT-SH) delivered at Step 2 in IAPT services has the potential to
reduce the cost of delivery and to widen access to people unable or unwilling to attend
a group[18]. This protocol is for a definitive RCT of clinical and cost effectiveness 
comparing MBCT-SH with CBT-SH for people experiencing mild to moderate 
depression. Our primary hypothesis is that supported MBCT-SH, in comparison to 
supported CBT-SH, will lead to greater reductions in depressive symptom severity 
from baseline to post-intervention. 
Secondary hypotheses are:
 MBCT-SH in comparison to CBT-SH will lead to greater reduction in depressive 
symptom severity from baseline to six-months follow-up. 
 A greater proportion of MBCT-SH participants will be in the non-clinical range 
for depressive symptoms than CBT-SH participants at post-intervention (i.e. 
remission) and six-months follow-up (i.e. recovery).  
 MBCT-SH in comparison to CBT-SH will lead to greater improvements in 
mindfulness, generalised anxiety, work and social adjustment and wellbeing from 
baseline to post-intervention and from baseline to six-months follow-up.
 Treatment completion rates will be higher for MBCT-SH than CBT-SH.
 Depressive symptom severity outcomes will be mediated by treatment completion.
 MBCT-SH will be cost-effective in comparison to CBT-SH at follow-up. 9
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 MBCT-SH will be a safe alternative to CBT-SH, with a similarly low incidence of
serious adverse events during therapy and lasting negative effects of therapy.
In the event that the primary hypothesis of MBCT-SH superiority over CBT-SH on 
the primary outcome is not supported an additional exploratory analysis will be 
carried out to explore non-inferiority of MBCT-SH compared to CBT-SH. 
A qualitative component will close the evidence gap concerning reasons for treatment 
non-completion in IAPT services by identifying facilitators and barriers to treatment 
completion in both arms. Qualitative interviews will be conducted using the Change 
Interview[19] to ascertain facilitators and barriers to treatment completion for each 
intervention. Questions were added to the end of interview following advice from the 
study’s lived experience Public and Patient Involvement (PPI) consultation panel. 
These questions enquire about participants’ experiences of their allocated intervention
beyond depressive symptom change. 
Methods/Design
Design and sample size
This is a parallel-groups, superiority pragmatic RCT with 1:1 allocation to MBCT-SH
or CBT-SH, with blinded assessments at all time points. Participants will be blind to 
the hypothesised direction of effects. Four hundred and ten people meeting eligibility 
criteria for major depressive disorder or mixed anxiety and depression will be 
randomly allocated to receive MBCT-SH or CBT-SH, along with six sessions of 
support from a PWP. Participants will complete measures at baseline (Time 0), 16 
weeks post-randomisation (post-intervention, Time 1) and 42 weeks post 
randomisation (6-months follow-up, Time 2). In addition, 24 participants will be 10
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interviewed about their experiences of both self-help interventions (12 participants per
arm) at Time 1 with a focus on better understanding barriers and facilitators to 
engaging in self-help interventions in IAPT services and investigating any negative 
experiences or effects of treatments.
The sample size was based on detecting a between-group effect size of 0.36 based on 
the difference between the reported between-group effect of CBT-SH (0.42)[20] and 
the reported between-group effect of MBCT-SH (0.78)[21]. Recruiting 205 patients 
into each arm would provide 90% power to detect a between-group difference of 0.36 
with a 5% alpha and a two-sided t-test whilst allowing for 20% attrition at post-
intervention (as found in our pilot study). Therefore, a total sample size of 410 will be
required. 
The study design was informed through consultation with a PPI group chaired by a 
PPI co-applicant consultant (LL). Members of the PPI group had participated in a 
pilot study of the intervention or had lived experience of depression, mindfulness and/
or CBT. The PPI group were instrumental in advising on a number of aspects of study
design including the frequency and nature of support sessions and the study 
recruitment strategy and materials.
Participants
Participants will be recruited through ten IAPT services across England. A list of sites
can be requested through the corresponding author.
11
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Inclusion criteria are that participants: (1) be aged 18 years or over; (2) meet 
diagnostic criteria on the revised Clinical Interview Schedule (CIS-R)[22] for a 
primary diagnosis of a depressive episode, mixed anxiety and depression, or non-
specified mild neurotic disorder; (3) score 10 or more on the PHQ-9[23] at their initial
IAPT assessment (cut-off indicating a probable major depressive episode); and (4) 
have sufficient literacy skills to read and understand the self-help materials.  
Exclusion criteria are that participants: (1) have severe symptoms of depression (a 
score 20 or more on the PHQ-9); (2) score of 4 on the CIS-R suicidality scale; and (3) 
express a strong preference (5/5) for one intervention over the other on the treatment 
preference question such that if randomised to the non-preferred intervention they 
would be likely to drop out of the intervention. 
Measures
Demographics
A questionnaire will be completed to collect demographic information. 
Diagnostic status
The Clinical Interview Schedule (CIS-R)[22] will be conducted at baseline (Time 0) to
ascertain diagnostic status. The CIS-R is routinely used in primary care mental health 
and IAPT research[1] and has been validated for telephone completion[24].
Primary Outcome Measure
Depression symptom severity (PHQ-9)[23]. The PHQ-9 is a 9-item self-report 
measure of depression symptom severity used in all IAPT services with good 
12
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sensitivity and specificity. Items are rated on a four-point scale. Scores under 10 are 
considered sub-clinical, 10-14 mild, 15-19 moderate and 20+ severe. The PHQ-9 will 
be administered at Time 0, Time 1 and Time 2.
Secondary Outcome Measure
Generalised anxiety (GAD-7)[25]. This is a 7-item measure of generalised anxiety 
used in IAPT. Items are rated on a 4-point scale and the measure has excellent 
psychometric properties[25]. This will be administered at Time 0, Time 1 and Time 2.
Wellbeing (SWEMWS)[26]. The short version of the Warwick Edinburgh Mental 
Wellbeing Scale consists of 7 questions rated on a 5-point scale designed to measure 
wellbeing. The scale has good psychometric properties and is used widely[27]. This 
measure was added following advice from the Public and Patient Involvement (PPI) 
consultation panel. This will be administered at Time 0, Time 1 and Time 2.
Functioning (WSAS)[28]. The Work and Social Adjustment Scale (WSAS) is a 5-item
measure of daily occupational and social functioning that is used routinely in IAPT. 
This will be administered at Time 0, Time 1 and Time 2.
Mindfulness (FFMQ-15)[29]. Mindfulness will be measured using 15-item version of 
the Five-Facet Mindfulness Questionnaire. This has excellent psychometric properties
and is sensitive to change following MBCT[29]. This will be administered at Time 0, 
Time 1 and Time 2.
13
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The Change Interview[19] will be used to guide the qualitative component of the 
study. This is a widely-used semi-structured interview designed to explore 
participants’ experiences of psychological interventions and has been successfully 
used in previous studies by members our team. Questions about participants’ 
experiences of the effects of their allocated intervention on personally-relevant 
outcomes (i.e. not necessarily restricted to depressive symptoms) have been added at 
the end of the interview following advice from the study’s lived experience 
consultation panel. The Change Interview will be conducted by the PPI consultant co-
applicant on the study (LL) with the expectation that this will facilitate participants to 
be open about their experiences of the study and interventions. This will be conducted
at Time 1.
Health Economic Measures
Service use. An adapted version of the Adult Service Use Schedule (AD-SUS) will be
used to measure individual-level all-cause hospital and community-based health and 
social care resource use. The AD-SUS was developed in previous research for use 
with people with common mental disorders[30,31] and adapted for the purpose of this
study. The baseline (Time 0) AD-SUS will cover the period 3 months prior to 
randomisation. At the Time 1 and Time 2 follow-up interviews, the AD-SUS will 
cover the period since last interview.
Health-related quality of life (EQ-5D-5L)[32]. The EQ-5D is a five-dimension, five-
level, generic, preference-based measure of health-related quality of life covering 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. We will 
14
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use the recently developed five level version, to maximise sensitivity[33]. This 
measure will be administered at Time 0, Time 1 and Time 2.
Intervention Evaluation Measures and Tools
Intervention expectation form. This will be used to assess expectation of benefit and 
treatment credibility at Time 0.
Lasting negative effects questionnaire. This will be used to ask participants about any 
lasting negative effects of their allocated intervention at Time 2.
PWP rating scale. This will be used for participants to rate the quality/helpfulness of 
the sessions between the participant and their PWP at Time 1.
Weekly diaries. These record the extent to which participants are engaging with the 
self-help course each week during intervention delivery.
Engagement questionnaire (end of treatment). This records the extent to which 
participants engaged with the self-help course during the entire course of the 
intervention and will be administered at Time 1. 
Engagement questionnaire (follow-up). This records the extent to which participants 
continued to engage with the self-help course following the end of the intervention 
and will be administered at Time 2.
15
RUNNING HEAD: LIGHTMind: MBCT-SH COMPARED TO CBT-SH FOR DEPRESSION
Session attendance. Number of PWP sessions attended (0-6) and duration of each 
support session.
Treatment completion. This is defined as attending at least 50% of the PWP sessions 
(i.e. attending at least 3 sessions).
Procedure
See Figure 1 for the SPIRIT Schedule of enrolment, interventions, and assessments. 
Patients with a diagnosis of depression will be sought through IAPT services. The 
study will also be advertised in General Practitioner surgeries and elsewhere. Self-
referrers will be guided to the study via their local IAPT service. Informed consent 
will be obtained from each participant. Potential participants will be given a copy of 
the study participant information sheet and will have the opportunity to discuss the 
study in person with the research assistant (RA) before signing the consent form (a 
copy of which can be obtained from the corresponding author). 
Once the participant has consented to participate in the trial, the participant will 
complete the full set of baseline measures with an RA present in person or by phone. 
Measures will be completed online or on paper, depending on participant preference. 
Participants who do not meet eligibility criteria at the baseline assessment will be 
referred back to the person who conducted their initial assessment for usual care to be 
offered by the service.
At the end of the baseline assessment, eligible participants will be randomised to 
either the MBCT-SH or CBT-SH arm. Participants will then be given their allocated 
self-help workbook. Randomisation will be stratified by centre and PHQ-9 score 16
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(mild or moderate) using random block length. Eligible participants will be randomly 
allocated using the Sealed Envelope[34] online service. The study statistician will use 
Sealed Envelope to set up and test the randomisation procedure incorporating 
stratification by site and PHQ-9 severity category (mild or moderate) using random 
block length and 1:1 allocation. The statistician will not have any further involvement 
in the randomisation process. The RA will randomise participants by completing the 
online form with participant’s details. This will immediately show whether the 
participant is assigned to the MBCT-SH or CBT-SH arm and participants will be 
given their self-help workbook. Participants will not be told the hypotheses in relation
to the arm to which they have been randomised. 
Participants will then guide themselves through their allocated intervention over the 
8-week course with six PWP support sessions. A maximum of 16 weeks is given for 
the intervention period to allow participants to complete their allocated 8-week course
to take account of breaks for holidays, sickness etc. PWP support sessions may be 
offered by phone or face-to-face, depending on usual practice in the service and 
participant preference. This mirrors the usual way in which self-help interventions are
offered in IAPT – i.e. offering a self-help workbook alongside a limited number of 
PWP support sessions.
Participants will complete measures online (with a postal option) at 16 weeks post-
randomisation (post-intervention, Time 1) and 42 weeks post-randomisation (6-month
follow-up, Time 2). Participants will have the option to choose whether to complete 
the Time 1 and Time 2 measures with an RA present in person or by phone (who will 
be blind to group allocation) or on their own. In the event that an RA is required to be 
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present during Time 1 or Time 2 assessments and becomes unblinded the assessment 
will be completed by another, blinded RA. Where Time 1 and Time 2 assessments are
not completed, participants will be contacted at weekly intervals for up to one month 
to remind them to complete these assessments, unless participants have discontinued 
from the study.
Twenty-four participants will be invited to take part in the qualitative Change 
Interview after their post-intervention (Time 1) quantitative assessment is completed. 
Participants will be interviewed on a first come, first served basis with 12 participants 
interviewed in each of two groups: (1) MBCT-SH intervention completers, and (2) 
CBT-SH intervention completers.
Therapy Protocols
MBCT Self-Help
The MBCT-SH workbook ‘The Mindful Way Workbook'[35], written for clinical 
populations, presents MBCT as a self-help package. MBCT-SH participants will be 
given the workbook and will be asked to guide themselves through the self-help 
course within a 16-week time period (the time period determined in our pilot). As is 
routine at Step 2, participants will be offered six PWP sessions to answer questions 
and provide encouragement. 
PWPs currently train in CBT-SH. To match training between arms we will offer PWP
training in MBCT-SH. The training involves PWPs: (1) attending an MBCT group as 
a participant and guiding themselves through the MBCT-SH workbook, or completing
the MBCT course using the workbook as a guide, and (2) attending a two-day 
18
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experiential mindfulness skills workshop. As is standard in delivering MBIs, PWPs 
will be encouraged to maintain their own personal mindfulness practice throughout 
the study, and this will be recorded using the PWP Mindfulness Practice Record. 
Fortnightly MBCT-SH group supervision for PWPs will be provided.
CBT Self-help
The CBT-SH workbook 'Overcoming Low Mood and Depression'[36] has evidence 
demonstrating its effectiveness in reducing depression symptom severity[37]. This 
workbook is often used at Step 2 in IAPT. 
Matched to the MBCT-SH condition, participants allocated to CBT-SH will be given 
a copy of their workbook and will be encouraged to guide themselves through within 
16 weeks alongside six PWP sessions to answer questions and provide 
encouragement. 
As in the MBCT-SH condition, fortnightly CBT-SH group supervision for PWPs will 
be provided.
Intervention Fidelity and Adherence
The same PWPs will deliver both interventions in order to minimise therapist effects, 
as some PWPs achieve substantially better outcomes than others. In order to minimise
therapeutic drift and therapy contamination the PWP protocols are detailed and there 
will be fortnightly supervision of PWPs. PWPs will be asked to audio record at least 
one complete MBCT-SH case and at least one complete CBT-SH case. A random 
10% sample of recordings from each PWP will be rated for fidelity to the therapy 
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protocols by a clinical psychologist trained in CBT and MBCT and who is 
independent of the PWP training and supervision.
 
Participants will be prompted each week by the research assistant to complete weekly 
diaries (online/paper versions) to record the amount of workbook read and time spent 
engaged in intervention tasks.
(Serious) Adverse Events Monitoring
A protocol for identifying and independently assessing serious adverse events will 
ensure that such events are addressed in a timely fashion and responded to, including 
if a serious adverse event is classified as potentially study-related. Serious adverse 
events and their classification will be reported to the Data Safety Monitoring Board 
(DSMB) and Trial Steering Committee (TSC) and action will be taken as deemed 
necessary.
Serious and other adverse events will be discussed in intervention supervision (with 
CS or FJ) and in service-based clinical supervision in the relevant IAPT service. 
Where deemed in the best interests of participants, the study intervention may be 
discontinued and other treatment options may be recommended by the IAPT service. 
Planned Data Analysis
The primary analysis will be a quantitative analysis of the primary outcome at the 
primary endpoint (Time 1) using an intention-to-treat approach (ITT) where 
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participants are analysed as per their randomisation allocation regardless of treatment 
received.
Secondary analyses will consist of ITT analyses of the primary outcome at the follow-
up time point (Time 2) and all secondary outcomes.  A per protocol analysis will also 
be carried out for those participants receiving an adequate dose of their allocated 
intervention, defined as attending at least 50% of the PWP sessions (i.e. at least 3 
sessions). 
A descriptive summary of all measures will be provided by group (MBCT-SH & 
CBT-SH) and time point (Time 0, Time 1 and Time 2) as appropriate.  Comparisons 
between groups for all measures will be carried out using independent t-tests and Chi-
square testing for continuous and categorical data, respectively. Unstandardised effect
sizes for the primary outcome and secondary outcomes will be estimated using linear 
mixed models with treatment group (MBCT-SH vs CBT-SH), time and a treatment 
group by time interaction entered as fixed factors; site, baseline PHQ-9 and baseline 
value of the outcome will be entered as covariates. Individual participants will be 
included in the analysis as random effects. Contrasts will be used as appropriate to 
estimate effects at different time points. A non-significant group by time interaction 
will imply common treatment effects at each time point.  
Standardised (Cohen’s d) effect sizes for each outcome will be calculated by dividing 
the between-group unstandardized effect by the baseline pooled standard deviation. 
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95% confidence intervals will be calculated for all unstandardised estimates. Group 
differences in dichotomous outcomes at the different time points will be analysed in a 
similar way but using multilevel logistic regression models and baseline PHQ-9 
scores. Baseline balance will be presented in the descriptive table broken down by 
study arm. No adjustment will be made for differences between co-variates at 
baseline.  Outliers will be removed if and only if they look erroneous. Scores at the 
extreme will not be removed if they are deemed to be true. The suitability of the 
assumption of approximate normality will be explored by plotting the residuals from 
this model. If normality is violated then transformations and non-parametric testing 
will be employed. A sensitivity analysis will be carried out by carrying out the final 
analysis on the primary outcome, with and without any individual cases what were 
involved in violations of the protocol.
Additional exploratory analysis 
In the event that there is no evidence to support the primary hypothesis of MBCT-SH 
superiority over CBT-SH on our primary outcome, an additional exploratory analysis 
will be carried out to explore non-inferiority of MBCT-SH compared to CBT-SH. The
analysis will be based on detecting a between-group non-inferiority margin of 2 points
on the PHQ-9 with a one-sided α = 0.025. To operationalise this, a two-sided 95% 
confidence interval will be created around the effect size (MBCT-SH – CBT-SH) and 
we will conclude non-inferiority if the upper limit of the CI is wholly below 2 PHQ-9 
points for both the PP and ITT analyses. The non-inferiority limit was set through 
consultation with service users and clinicians and looking at the literature [38,39] 
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Data entry accuracy and missing data
We aim to minimise missing data and data entry inaccuracies at the point of 
collection. The Qualtrics online survey software used to collect all data will 
automatically flag any unanswered questions, giving participants to chance to answer 
these. If a participant would prefer not to answer a question they can leave it 
unanswered for a second time and the software will proceed onto the next page. At the
point of analysis data will be summarised to look at patterns of missingness. Missing 
data will be replaced using multiple imputation as appropriate. Missing data will be 
assessed and if more than 5% of data is missing multiple imputation will be carried 
out followed by a sensitivity analysis. The sensitivity analysis will compare the results
for a complete case analysis to the imputed data analysis. Multiple imputation will be 
carried out under the assumption the data is missing at random (MAR). Anonymised 
data will be stored on the Qualtrics platform and on password-protected NHS and 
university computers. Personal data will be stored securely in locked filing cabinets in
NHS research offices and on password protect NHS computers. 
Planned interim analysis and stopping rules
No interim analysis has been planned.  The trial will be paused or stopped if deemed 
necessary by the DSMB.
Multiple testing
There shall be no multiple testing.
Economic Evaluation
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The economic evaluation will be conducted covering the period from Time 0 to Time 
2 and will take the NHS/personal social services perspective preferred by NICE[40]. 
Resource use data from the AD-SUS will be combined with unit costs to calculate the 
total costs of the MBCT-SH and CBT-SH groups. The cost of the two interventions, 
MBCT-SH and CBT-SH, will be calculated using a micro-costing approach[41] based
on PWPs’ salary, including relevant on-costs and overheads. Data on the number and 
duration of PWP contacts in the MBCT-SH and CBT-SH arms will be recorded using 
a proforma completed by PWPs. Data on indirect time, including preparation and 
supervision, will be collected directly from the PWPs. All other health and social care 
services will be costed using nationally applicable published unit costs, such as the 
NHS Reference Costs for hospital costs, the British National Formulary for 
medication and the PSSRU Unit Costs of Health and Social Care.
 
Costs and outcomes will be compared and presented in terms of mean differences and 
95% confidence intervals obtained by non-parametric bootstrap regression to account 
for the non-normal distribution commonly found in economic data[42]. Cost -
effectiveness will be assessed through the calculation of incremental cost-
effectiveness ratios and will be explored in terms of quality-adjusted life years 
(QALYs) calculated from the EQ-5D-5L and using the area under the curve 
approach[43]. Uncertainty will be explored using cost-effectiveness planes and cost-
effectiveness acceptability curves based on the net-benefit approach[44,45]. These 
curves are an alternative to confidence intervals around ICERs and show the 
probability that one intervention is cost-effective compared to the other, for a range of
values that a decision maker would be willing to pay for an additional unit of an 
outcome. All economic analyses will include relevant baseline variables to provide a 
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more relevant treatment-effect estimate[46]. The primary analysis will include those 
with complete data needed to be included in the economic evaluation. Sensitivity 
analyses will explore the impact of missing data.
Qualitative Data Analysis
Qualitative data will be analysed using Thematic Analysis[47] in order to identify 
facilitators and barriers to treatment completion for each intervention arm. Analysis 
will be informed by the structure of the Change Interview[19], but it will also be able 
to identify inductively-derived themes reflecting participants’ experiences. 
Discussion
Cognitive Behavioural Therapy self-help (CBT-SH), supported by a psychological 
wellbeing practitioner (PWP), is the usual treatment offered in IAPT services to 
people with mild/moderate symptoms of depression. However, over half of people 
who complete this treatment remain depressed and, furthermore, less than half of 
IAPT service users complete treatment. This results in disappointing treatment 
outcomes for many service users and increasing costs for mental health services in 
primary care. Finding an alternative, more effective self-help treatment would lead to 
better outcomes for service users and a more efficient use of NHS resources. 
MBCT-SH differs from CBT-SH in focus, approach and practice, but it may still be 
able to be delivered in IAPT services with support from PWPs. By teaching service-
users the ability to intentionally pay attention, non-judgementally, to current 
experience, MBIs aim to reduce rumination and worry, key components of 
depression, by teaching the application of mindfulness in everyday life and work. 
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MBCT-SH, therefore, offers a potentially viable and more effective alternative to 
CBT-SH for improving both outcomes for service users and treatment completion 
rates. 
This definitive randomised control trial directly compares MBCT-SH to CBT-SH 
with the primary aim of determining the clinical and cost effectiveness of MBCT-SH 
at reducing depression symptom severity compared to CBT-SH. There is also much 
less known about the effectiveness of supported self-help mindfulness-based 
interventions in comparison to their in-person group-based counterparts and so this 
trial will advance understanding in this area. If the primary superiority hypothesis is 
not supported, the exploratory non-inferiority analysis will help elucidate if MBCT-
SH may be non-inferior to current best practice (i.e. CBT-SH) and therefore findings 
will be of clinical relevance. Findings from the Change Interview will highlight 
facilitators and barriers to engagement in both MBCT-SH and CBT-SH and will 
hopefully lead to recommendations for maximising engagement to both these 
interventions. 
The results of this trial will provide valuable evidence to inform clinical practice and 
commissioners of services. This could enable a greater choice in effective treatment 
options for IAPT service users, help elucidate issues around why some people are 
unable to complete treatment and allow for a more efficient use of NHS resources. 
The results will also provide evidence more generally about mindfulness-based 
interventions, their clinical and cost effectiveness, and the mechanisms of change 
which underpin them.
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Trial status 
At the time of manuscript submission, recruitment for this study was ongoing. 
Recruitment started on 1 December 2017 and is due to be completed on 31 January 
2020.
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Figure 1.  Schedule of enrolment, interventions, and assessments
Enrolment Allocation InterventionPeriod
Post-
intervention
Follow-up
and Close
TIMEPOINT Time 0 Time 1 Time 2
ENROLMENT:
Informed Consent X
Allocation X
INTERVENTIONS:
MBCT-SH X
CBT-SH X
ASSESSMENTS:
Baseline
Assessment X
Post-intervention
Assessment X
Follow-up
Assessment X
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